Insider · SEC Form 4 filer
James Huang
Companies
Where they file as an insider
Connect Biopharma (CNTB) Director Latest filing May 29, 2026
Atara Biotherapeutics (ATRA) Director, 10% owner Latest filing Jan 12, 2026
Track record
Did their buys beat the typical stock?
Open-market buys3
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check1
Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.
Connect Biopharma (CNTB) Bought May 29, 2026 · $372K · 150,000 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Connect Biopharma (CNTB) Bought Mar 31, 2026 · $4M · 1.16M shares Behind typical Mar 31, 2026 $2.62 → Sep 30, 2026 $1.10 · −58.0% (typical stock +1.7%)
Atara Biotherapeutics (ATRA) Bought Jul 17, 2025 · $186K · 19,335 shares Not counted Not counted. We have no fund price for this stock on both Sep 30, 2025 and Mar 31, 2026.
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.